FDA Fast Tracks Gene Therapy for Chronic Angina Patients – Monthly Prescribing Reference (registration)
|
FDA Fast Tracks Gene Therapy for Chronic Angina Patients
Monthly Prescribing Reference (registration) XC001 is an investigational cardiovascular angiogenic gene therapy that promotes angiogenesis to provide arterial blood flow to myocardial regions with inadequate blood supply. This enhanced blood flow is intended to relieve myocardial ischemia … FDA Grants Fast Track Designation to XyloCor Therapeutics Lead Candidate XC001 |
